Those taking the drugs for at least three years cut their risk of heart attack, stroke or cardiac death by 20 per cent ...
The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
Weight loss jabs like Ozempic cuts risk of heart attack and stroke by fifth, ‘game-changing’ study finds - Risk of serious ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Ozempic could dramatically reduce the risk of heart attacks and stroke, a new study indicates. The weight loss jab has become ...
A study has found the anti-obesity drug sold under brand names Wegovy, Ozempic and Rybelsus could reduce the risk of heart attacks, strokes ...
A weight loss injection could reduce the risk of heart attacks and benefit the cardiovascular health of adults, according to a study on what could be the largest medical breakthrough since statins.
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
A powerful anti-obesity jab has been found to slash the risk of chronic disease regardless of the amount of weight lost.